Head to Head Review: DURECT Corporation (DRRX) vs. Its Peers

DURECT Corporation (NASDAQ: DRRX) is one of 288 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare DURECT Corporation to related companies based on the strength of its earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Profitability

This table compares DURECT Corporation and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DURECT Corporation -221.01% -629.35% -85.43%
DURECT Corporation Competitors -4,766.74% -354.83% -43.39%

Volatility & Risk

DURECT Corporation has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, DURECT Corporation’s competitors have a beta of 6.57, suggesting that their average stock price is 557% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for DURECT Corporation and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DURECT Corporation 0 0 3 0 3.00
DURECT Corporation Competitors 1377 4466 12277 311 2.63

DURECT Corporation currently has a consensus price target of $3.17, indicating a potential upside of 96.69%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 34.40%. Given DURECT Corporation’s stronger consensus rating and higher probable upside, equities analysts clearly believe DURECT Corporation is more favorable than its competitors.

Insider & Institutional Ownership

45.8% of DURECT Corporation shares are owned by institutional investors. Comparatively, 51.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 10.3% of DURECT Corporation shares are owned by insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares DURECT Corporation and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
DURECT Corporation $16.15 million -$33.04 million -6.44
DURECT Corporation Competitors $464.68 million $167.54 million -6.58

DURECT Corporation’s competitors have higher revenue and earnings than DURECT Corporation. DURECT Corporation is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

DURECT Corporation competitors beat DURECT Corporation on 8 of the 12 factors compared.

DURECT Corporation Company Profile

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company’s ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.

Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply